Patent Filing

With Cigna's backing, Accord's IMULDOSA is set to challenge a blockbuster drug, promising significant savings for patients and the healthcare system.

Hologram firm HOLO unveils a simplified quantum authentication method, backed by a massive investment to challenge the future of cybersecurity.

A veteran-owned firm's deal with DHS could replace facial recognition at airports, driven by a political push for privatization and privacy-first tech.

RIMAN's parent company is partnering with Harvard to test a new ingredient on 'organ-on-a-chip' tech, a move set to redefine evidence in skincare.

FDA approves the first generic of a vital nutrition drug, granting Apotex a 180-day exclusive edge and signaling major cost savings for healthcare.

Replimune halts a promising cancer therapy and cuts jobs after a stunning FDA rejection, citing a 'failed' system and inconsistent regulatory process.

A new IP firm, led by an industry veteran, acquired 500+ Avaya networking patents. The move signals a new era for tech licensing and innovation.

Lupin has launched a generic version of the blockbuster diabetes drug Farxiga, signaling lower costs for patients and a major shake-up in the SGLT2 market.

With its lead drug in Phase 3 and a strong Biogen partnership, Stoke Therapeutics prepares to update investors on its disease-modifying Dravet syndrome therapy.

Facing a shareholder revolt after a damning indictment, Supermicro launches a major probe into a $2.5B shadow trade scheme. Is it too little, too late?

Lupin wins FDA approval for its generic dapagliflozin, a move set to slash costs for a blockbuster diabetes and heart drug and reshape patient care.

Vyome is set to present promising Phase 2 data for VT-1953, a first-in-class treatment for a debilitating cancer complication with no approved drugs.

A breakthrough test for Parkinson's is expanding worldwide, promising earlier, more accurate diagnoses and accelerating the hunt for a cure.

With its lead drug for a rare pediatric liver disease entering late-stage trials, NorthSea Therapeutics adds a veteran drug developer to its board.

A new, imageable liver cancer therapy is one step closer to patients, thanks to a strategic partnership securing a vital US-based medical isotope supply.

A new partnership provides early access to an investigational drug for FAP, offering a potential non-surgical therapeutic option for the first time.

A new, highly selective oral drug for the most common form of dwarfism has been cleared for U.S. trials, offering hope for a more convenient treatment.

After its pivotal trial for ersodetug missed its primary endpoint, Rezolute gets a rare nod from the FDA to submit full data, igniting new hope.

A landmark partnership is scaling a 'one-drug, many-diseases' therapy, revealing how logistics, not just labs, are key to the future of medicine.

ECOX is rebranding and moving into Sustainable Aviation Fuel, but financial transparency questions and major hurdles stand in the way of its ambitious plans.